STOCK TITAN
  1. Home
  2. Sec-filings
  3. GYRE
  4. [Form 4] GYRE THERAPEUTICS, INC. Insider Trading Activity

Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. director Zhang Ping received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $5.95 per share, expire on June 10, 2036, and vest in 12 equal monthly installments through June 10, 2027 as long as service continues.

Positive

  • None.

Negative

  • None.
Insider Zhang Ping
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 40,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 40,000 options Stock Option (Right to Buy) awarded to director Zhang Ping
Exercise price $5.95 per share Exercise price for the 40,000 stock options
Expiration date June 10, 2036 Option term end date for the grant
Vesting period end June 10, 2027 Vests in 12 equal monthly installments through this date
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 5.9500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest in 12 equal monthly installments financial
"will vest in 12 equal monthly installments through June 10, 2027"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zhang Ping
(Last)(First)(Middle)
C/O GYRE THERAPEUTICS, INC.
12730 HIGH BLUFF DRIVE, SUITE 250
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.9506/10/2026A40,000 (1)06/10/2036Common Stock40,000$040,000D
Explanation of Responses:
1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.
/s/ Thomas Eastling, as attorney-in-fact for Ping Zhang06/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Zhang Ping report in this Form 4 for GYRE?

Zhang Ping reported receiving a grant of stock options for 40,000 shares of Gyre Therapeutics common stock. These options are a compensation award, not an open-market stock purchase or sale, and give the right to buy shares at a fixed exercise price.

What is the exercise price of Zhang Ping’s GYRE stock options?

The stock options have an exercise price of $5.95 per share. This means Zhang Ping can buy Gyre Therapeutics common stock at $5.95, regardless of future market price, once each portion of the option has vested and before the options expire.

How many GYRE shares are covered by Zhang Ping’s option grant?

The option grant covers 40,000 shares of Gyre Therapeutics common stock. Each option represents the right to purchase one share at the stated exercise price, subject to vesting conditions and the expiration date disclosed in the Form 4 filing.

When do Zhang Ping’s GYRE stock options vest and expire?

The options vest in 12 equal monthly installments through June 10, 2027, as long as Zhang Ping continues to serve the company. The options expire on June 10, 2036, after which any unexercised portion can no longer be used to buy shares.

Is Zhang Ping’s Form 4 transaction a stock purchase or sale of GYRE shares?

The Form 4 reports a stock option grant, not a direct stock purchase or sale. Zhang Ping acquired derivative securities (options) as compensation, giving the right to buy Gyre Therapeutics shares in the future rather than trading shares in the market.